Industry & Policy News

[CBC News] A new machine at Windsor Regional Hospital could help deliver 26,000 more cancer treatments a year. The hospital's new linear accelerator is a new, state-of-the-art machine that delivers targeted radiation treatments to people with cancer.

[GSK] GSK plc announced a major new research collaboration with the UK DRI and HDR UK to advance understanding of neurodegeneration with a first-of-its-kind dementia study.

[Wugen, Inc.] Wugen, Inc. announced the dosing of the first patients in its pivotal Phase II study evaluating WU-CART-007, a potential first-in-class, investigational, anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

[Forbes] A 21 year old man in New York has been cured of sickle cell anemia following treatment with a pioneering gene theray. New York resident Sebastien Beauzile was treated with a new gene therapy approach called Lyfgenia, developed by biotech company Bluebird Bio.

[Terumo BCT] Terumo Blood and Cell Technologies (Terumo BCT) signed a memorandum of understanding with Osong Medical Innovation Foundation toward joint development of workforce training for cell and gene therapy manufacturing. The partners will begin by creating programs to support the manufacture of MSC and chimeric antigen (CAR) T cell therapies.

[Nature Cell Co, Ltd. (ACCESS Newswire)] Nature Cell Co., Ltd., announced that JointStem has been granted Breakthrough Therapy Designation from the US FDA- the first instance for a Korean company in the field of cell therapy. JointStem is distinguished as the world's first autologous adipose-derived MSC therapy intended for patients with knee osteoarthritis.